Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oleclumab + Osimertinib or AZD4635 in Advanced EGFRm NSCLC
NCT03381274Phase 2Active, not recruiting
- Sponsor
- MedImmune
- Start
- May 2018
- Primary completion
- May 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label trial of oleclumab in non-small cell lung cancer (NSCLC), sponsored by MedImmune. Primary endpoints: Dose-limiting Toxicities, Treatment Emergent Adverse Events and Treatment Emergent Serious Adverse Events and 4 more. Started May 2018; status: active, not recruiting.
02
Drugs
oleclumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03381274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381274.